MedTrace Logo

Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris

NCT03039751 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-01-13

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and efficacy of catheter mediated endocardial adenovirus-mediated vascular endothelial growth factor-D (AdVEGF-D) regenerative gene transfer in patients with refractory angina to whom revascularisation cannot be performed.

Conditions

Interventions

DRUG

AdvVEGF-D

AdvVEGF-D will be injected into 10 sites of the myocardium

DRUG

Control Rx

Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium

Sponsors & Collaborators

  • Queen Mary University of London

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • Medical University of Vienna

    collaborator OTHER

  • Servicio Madrileño de Salud, Madrid, Spain

    collaborator OTHER

  • FinVector Vision Therapies Oy

    collaborator UNKNOWN

  • Śląski Uniwersytet Medyczny w Katowicach

    collaborator UNKNOWN

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Euram Limited

    collaborator UNKNOWN

  • Kuopio University Hospital

    lead OTHER

Principal Investigators

  • Seppo Ylä-Herttuala · Kuopio University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-19
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Denmark
  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03039751 on ClinicalTrials.gov